3 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 6 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Atypical Chronic Myeloid Leukemia: new trials by email Literature Review of Atypical Chronic Myeloid Leukemia trials Research Report on Atypical Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor Ruxolitinib, Abatacept (Orencia) - Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 60 | 2025-05-10 | 2025-11-20 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells - Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 33 | 2021-02-15 | 2026-02-17 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant Hyperbaric oxygen - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Omar Aljitawi | 24 | 2020-07-01 | 2026-06-03 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Carboplatin, Topotecan, Topotecan Hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2018-09-24 | 2026-06-23 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Pacritinib, Decitabine - Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia | Phase 1 | Withdrawn | Washington University School of Medicine | 2017-06-01 | 2017-05-08 | |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (8) · Leukemia, Myelomonocytic, Chronic (7) · Myeloproliferative Disorders (5) · Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4) · Myelodysplastic-Myeloproliferative Diseases (4) · Primary Myelofibrosis (4) · Graft vs Host Disease (2) · Leukemia, Myelomonocytic, Juvenile (2) · Thrombocythemia, Essential (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1)
Bone Marrow Diseases (8) · Chronic Disease (8) · Disease Attributes (8) · Hemic and Lymphatic Diseases (8) · Leukemia (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Hematologic Diseases (7) · Leukemia, Myeloid (7) · Myelodysplastic-Myeloproliferative Diseases (4) · Blood Platelet Disorders (3) · Myeloproliferative Disorders (3) · Blood Coagulation Disorders (2)
Biopsy (2) · Specimen Handling (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Abatacept (1) · Azacitidine (1) · Beclomethasone (1) · Carboplatin (1) · Decitabine (1) · Geriatric Assessment (1) · Hyperbaric Oxygenation (1) · Methotrexate (1) · Tacrolimus (1) · Topotecan (1) · Transplantation Conditioning (1) · axatilimab (1)
Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Omar Aljitawi (1) · St. Petersburg State Pavlov Medical University (1) · Uma Borate (1) · Washington University School of Medicine (1)
United States (6) · Russia (1)
Camille Abboud, M.D. (1) · Keith W Pratz (1) · Omar S Aljitawi, MBBS (1) · Paul Martin (1) · Richard J Lin, MD, PhD (1) · Uma M Borate, MD (1) · Wanxing Chai-Ho, MD (1)
UM1CA186691 (1)